Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.

Original publication

DOI

10.1038/bjc.1985.100

Type

Journal article

Journal

Br j cancer

Publication Date

05/1985

Volume

51

Pages

665 - 669

Keywords

Adult, Aged, Alkaline Phosphatase, Bone Neoplasms, Calcium, Clodronic Acid, Creatinine, Diphosphonates, Female, Humans, Hypercalcemia, Male, Middle Aged, Osteolysis